Investor Presentaiton
NAO
In the full year 2022, Rybelsus® sales account for 24%
share of growth of NAO sales
Total Rybelsus® TRx volume is steadily growing in the US
137
Investor presentation Full year 2022
RybelsusⓇ and SGLT-2i¹ uptake in the US² since respective launches
TRX count
(000s)
100
80
60
60
60
40
40
20
20
Rybelsus® TRX
SGLT-2i TRX
82
0
0
31
62
тури
65
•
93
124
155
Time since launch (weeks)
•
Successful RybelsusⓇ launch despite COVID-19
impacting the first year of launch
RybelsusⓇ TRX continues to steadily increase
.
Achieved global blockbuster status in 2022
1SGLT-2i is an average of empagliflozin and canagliflozin script count. 2RybelsusⓇ is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: TRx: Total prescription data; NAO: North America Operations; Source: IQVIA Xponent, Week ending 6th Jan 2023View entire presentation